Financial Performance - Operating revenue for the first nine months of 2024 reached ¥196,755,675.33, representing an increase of 18.20% year-on-year[4]. - Net profit attributable to shareholders for the first nine months of 2024 was ¥37,401,751.95, a decrease of 6.98% compared to the same period last year[4]. - The net profit after deducting non-recurring gains and losses for the first nine months of 2024 increased by 28.87% to ¥34,335,794.72[4]. - In Q3 2024, operating revenue was ¥59,345,733.11, a significant increase of 37.17% compared to Q3 2023[4]. - Net profit attributable to shareholders in Q3 2024 surged by 126.85% to ¥8,276,489.83 compared to the same quarter last year[4]. - Total operating revenue for the first nine months of 2024 reached ¥196,755,675.33, an increase from ¥166,457,498.73 in the same period of 2023, representing a growth of approximately 18.2%[19]. - Total operating costs for the first nine months of 2024 were ¥159,583,009.37, compared to ¥140,399,072.03 in 2023, indicating an increase of about 13.7%[19]. - The total profit for the first nine months of 2024 was ¥43,866,695.01, compared to ¥47,486,460.72 in the same period of 2023, a decrease of approximately 7.0%[21]. - The net profit for the first nine months of 2024 was ¥38,357,159.80, compared to ¥41,683,528.09 in the same period of 2023, indicating a decrease of about 7.8%[22]. - The basic earnings per share for the current period was ¥0.67, down from ¥0.76 in the previous period, reflecting a decline of approximately 11.8%[21]. Cash Flow - Cash flow from operating activities for the first nine months of 2024 was ¥31,770,713.86, down 10.54% year-on-year[4]. - Operating cash inflow for the first nine months of 2024 reached ¥222,179,458.95, an increase of 16.67% compared to ¥190,445,567.09 in the same period of 2023[23]. - Net cash flow from operating activities was ¥31,770,713.86, down 10.3% from ¥35,512,165.26 in the previous year[25]. - Cash inflow from investment activities surged to ¥489,147,049.64, a significant increase from ¥91,411,476.59 in the prior year, reflecting a growth of 435.5%[25]. - Cash outflow for investment activities totaled ¥444,654,169.87, compared to ¥238,977,029.03 in the same period last year, marking an increase of 86.0%[25]. - The net cash flow from investment activities was ¥44,492,879.77, a recovery from a negative cash flow of ¥147,565,552.44 in the previous year[25]. - Cash and cash equivalents at the end of the period increased to ¥119,883,840.96, compared to ¥51,670,475.05 at the end of the previous year, representing a growth of 131.7%[25]. - Total cash inflow from operating activities for the parent company was ¥181,549,198.21, up from ¥149,721,854.44 in the same period last year, reflecting a growth of 21.3%[26]. - The parent company's net cash flow from operating activities was ¥13,883,415.40, down 57.4% from ¥32,552,308.33 in the previous year[27]. - Cash inflow from investment activities for the parent company was ¥489,129,812.69, a substantial increase from ¥91,350,194.31 in the prior year, indicating a growth of 436.0%[27]. - The net increase in cash and cash equivalents for the parent company was ¥43,692,859.08, compared to a decrease of ¥5,126,819.76 in the same period last year[27]. Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥529,463,092.56, a decrease of 0.74% compared to the end of the previous year[4]. - The company's total assets as of September 30, 2024, were ¥487,135,067.03, compared to ¥475,167,774.71 at the end of 2023, showing an increase of about 2.0%[18]. - The total current assets rose to CNY 365,000,301.50, compared to CNY 359,432,671.62 at the end of 2023, indicating a growth of about 1.6%[12]. - The company's total liabilities decreased to CNY 48,511,925.10 from CNY 66,215,014.88, reflecting a reduction of about 26.8%[13]. - Total liabilities decreased to ¥27,997,648.40 as of September 30, 2024, from ¥32,322,967.10 at the end of 2023, a reduction of approximately 13.5%[17]. - The total equity attributable to shareholders increased to ¥459,137,418.63 as of September 30, 2024, compared to ¥442,844,807.61 at the end of 2023, marking a growth of about 3.7%[18]. - The company's cash and cash equivalents increased significantly to CNY 123,863,440.96 from CNY 68,776,270.48, representing an increase of approximately 80.2%[12]. - The company's inventory decreased slightly to CNY 91,020,522.94 from CNY 91,503,549.77, a decline of approximately 0.5%[12]. - The company's accounts payable decreased to CNY 28,332,767.72 from CNY 35,700,553.91, a decline of approximately 20.7%[13]. - The company’s non-current assets totaled CNY 164,462,791.06, down from CNY 173,962,722.13, indicating a decrease of about 5.5%[13]. Research and Development - Research and development expenses for the year-to-date totaled ¥15,384,389.34, an increase of 36.30%[5]. - Research and development expenses for the first nine months of 2024 amounted to ¥15,384,389.34, up from ¥11,287,408.84 in 2023, reflecting a growth of approximately 36.5%[19]. - The company’s research and development expenses for the first nine months of 2024 were ¥7,290,922.19, compared to ¥8,146,100.52 in the same period of 2023, a decrease of approximately 10.5%[21]. Strategic Moves - The company executed a share buyback program, which was timely disclosed, indicating a strategic move to enhance shareholder value[11]. - The company reported no significant legal disputes or financial guarantees during the reporting period, ensuring a stable operational environment[11]. - The company has not engaged in any major acquisitions or asset sales during the quarter, maintaining its current strategic focus[11].
峆一药业(430478) - 2024 Q3 - 季度财报